SAN MATEO, CA - October 27, 2003 - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported positive data from a triple therapy pilot study showing ZADAXIN® in combination with pegylated interferon alpha and ribavirin produced a 12-week early virologic response (EVR) in 61% of hepatitis C non-responder patients who had failed to respond to prior therapy of interferon in combination with ribavirin. By comparison, separate recent studies show that pegylated interferon alpha plus ribavirin produce an EVR in approximately 15-21% of non-responders and a sustained viral response (SVR) in only approximately 10% of such patients. A patient's EVR is considered necessary to achieve a sustained response, but evidence shows that a patient who demonstrates an EVR may or may not achieve a SVR, and therefore EVR may not be predictive of a successful outcome, especially for a non-responder. SVR is the absence of hepatitis C virus measured six months after ending therapy.

Dr. Eduardo Martins, Vice President of Medical Affairs of SciClone Pharmaceuticals, commented, "This is the first triple therapy study to evaluate ZADAXIN in combination with pegylated interferon alpha and ribavirin. These positive 12-week data support our previous data showing ZADAXIN used in combination with standard therapies has improved response rates for non-responders. We intend to analyze subsequent data from this study as well as consider future additional triple therapy studies. However, our primary clinical focus continues to be our two U.S. phase 3 clinical trials targeting ZADAXIN in combination with pegylated interferon alpha to be the first FDA approved therapy to specifically address the needs of non-responders."

The 12-week interim results from this triple therapy study were presented at the largest meeting of liver specialists in the world, the annual meeting of the American Association of the Study of Liver Disease (AASLD) on Saturday, October 25, 2003. This ongoi
'"/>

Contact: Angela Bitting
a.bitting@comcast.net
925-462-1106
AB Corporate Communications
27-Oct-2003

Page: 1 2 3 4
Related biology news :

1. Equine clonings triple play sheds light on calcium, cell signaling, human disease
2. Madagascar to triple areas under protection
3. DNA-based vaccine triples survival for dogs with melanoma
4. 2 Million of yeast to triple available drug treatments
5. North Atlantic study reveals food fish catches have declined by half - despite tripled fishing effort
6. Targeted therapy knocks out pediatric brain cancer in mice
7. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
8. Columbia research to examine gene influence on severity of peridontal disease, therapy response
9. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
10. The search for a kinder, gentler chemotherapy
11. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart